PMID- 33253679
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20231213
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 891
DP  - 2021 Jan 15
TI  - Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib 
      resistance in human multiple myeloma cells.
PG  - 173752
LID - S0014-2999(20)30844-X [pii]
LID - 10.1016/j.ejphar.2020.173752 [doi]
AB  - The overall survival of multiple myeloma (MM) patients significantly improved 
      with the use of proteasome inhibitor such as bortezomib. However, resistance to 
      sorafenib limits its use. Bortezomib-resistant MM cells were generated and their 
      bortezomib-resistant properties were confirmed by cell viability and apoptosis 
      assays. To explore functions and underlying mechanisms of long non-coding RNA 
      nuclear paraspeckle assembly transcript 1 (NEAT1) on bortezomib resistance in MM, 
      MTT assays,  fl ow cytometry analyses, dual luciferase report gene assays, RNA 
      pulldown assays and chromatin immunoprecipitation assays were carried out. NEAT1 
      and specific protein 1 (Sp1) was upregulated while miR-29b-3p was down regulated 
      in bortezomib-resistant MM cells. NEAT1 promoted Sp1 expression by sponging 
      miR-29b-3p and then enhanced the tolerance of MM cells to bortezomib. Sp1 
      targeted to NEAT1 promoter region promoting NEAT1 transcription and formed a 
      positive feedback loop. NEAT1 and Sp1 levels were higher and miR-29b-3p was 
      levels were lower in bortezomib-resistant MM patients. NEAT1/miR-29b-3p/Sp1 
      feedback loop enhanced the tolerance of MM cells to bortezomib. These results 
      indicate potentially valuable targets for overcoming bortezomib resistance for 
      MM.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Che, Feifei
AU  - Che F
AD  - Department of Hematology, Sichuan Provincial People's Hospital, University of 
      Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan 
      Translational Medicine Research Hospital, Chengdu, 610072, Sichuan, China. 
      Electronic address: Chefeifei2@126.com.
FAU - Ye, Xuemei
AU  - Ye X
AD  - Department of Hematology, Dongli Medical District of Sichuan Provincial People's 
      Hospital, University of Electronic Science and Technology of China, Chinese 
      Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, 
      610051, Sichuan, China.
FAU - Wang, Yu
AU  - Wang Y
AD  - Department of Hematology, Dongli Medical District of Sichuan Provincial People's 
      Hospital, University of Electronic Science and Technology of China, Chinese 
      Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, 
      610051, Sichuan, China.
FAU - Ma, Shuyue
AU  - Ma S
AD  - Department of Hematology, Dongli Medical District of Sichuan Provincial People's 
      Hospital, University of Electronic Science and Technology of China, Chinese 
      Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, 
      610051, Sichuan, China.
FAU - Wang, Xuemei
AU  - Wang X
AD  - Department of Hematology, Dongli Medical District of Sichuan Provincial People's 
      Hospital, University of Electronic Science and Technology of China, Chinese 
      Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, 
      610051, Sichuan, China.
LA  - eng
PT  - Journal Article
DEP - 20201128
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Antineoplastic Agents)
RN  - 0 (MIRN29a microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (NEAT1 long non-coding RNA, human)
RN  - 0 (Proteasome Inhibitors)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (Sp1 Transcription Factor)
RN  - 0 (SP1 protein, human)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Bortezomib/*pharmacology
MH  - Case-Control Studies
MH  - Cell Line, Tumor
MH  - *Drug Resistance, Neoplasm/genetics
MH  - Feedback, Physiological
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - MicroRNAs/genetics/*metabolism
MH  - Multiple Myeloma/*drug therapy/genetics/metabolism/pathology
MH  - Proteasome Inhibitors/*pharmacology
MH  - RNA, Long Noncoding/genetics/*metabolism
MH  - Sp1 Transcription Factor/genetics/*metabolism
OTO - NOTNLM
OT  - Bortezomib
OT  - Multiple myeloma
OT  - NEAT1
OT  - Resistance
OT  - Sp1
OT  - miR-29b-3p
EDAT- 2020/12/01 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/11/30 20:10
PHST- 2020/09/16 00:00 [received]
PHST- 2020/11/17 00:00 [revised]
PHST- 2020/11/19 00:00 [accepted]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
PHST- 2020/11/30 20:10 [entrez]
AID - S0014-2999(20)30844-X [pii]
AID - 10.1016/j.ejphar.2020.173752 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2021 Jan 15;891:173752. doi: 10.1016/j.ejphar.2020.173752. Epub 
      2020 Nov 28.